Recent advances in the internal medical management of extranodal nasal type NK/T cell lymphoma

Abstract

Abstract:Extranodal nasal type NK/T cell lymphoma (ENKTL) is a highly aggressive nonHodgkin lymphoma. Due to its low occurrence even in prevalent areas, there has been no large sample randomized controlled clinical trials. Therefore, no standard therapeutic strategy is currently identified in this disease. Tumor cells are insensitive to conventional anthracyclinescontaining chemotherapy because of high expression of multidrug resistant gene 1. Regimens that incorporate the use of Lasparaginase or gemcitabine result in substantial improvements in overall response rate and are promising treatment for ENKTL. Targeted therapy, immunomodulatory therapy and hematopoietic stem cell transplantation are still under research.

Key words:Lymphoma, extranodal NK T cell,Drug therapy,Hematopoietic stem cell transplantation

Wang Jingjing, Dong Mei. Recent advances in the internal medical management of extranodal nasal type NK/T cell lymphoma[J]. Journal of International Oncology, 2015, 42(1): 71-73.

References

［1］ Vose J, Armitage J, Weisenburger D, et al. International peripheral Tcell and natural killer/Tcell lymphoma study: pathology findings and clinical outcomes［J］. J Clin Oncol, 2008, 26(25): 4124-4130. ［2］ Li YX, Liu QF, Wang WH, et al. Failure patterns and clinical implications in early stage nasal natural killer/Tcell lymphoma treated with primary radiotherapy［J］. Cancer, 2011, 117(22): 5203-5211. ［3］ Wang B, Li XQ, Ma X, et al. Immunohistochemical expression and clinical significance of Pglycoprotein in previously untreated extranodal NK/Tcell lymphoma, nasal type［J］. Am J Hematol, 2008, 83(10): 795-799. ［4］ Yamaguchi M, Suzuki R, Kwong YL, et al. Phase Ⅰ study of dexamethasone, methotrexate, ifosfamide, Lasparaginase, and etoposide (SMLILE) chemotherapy for advancedstage, relapsed or refractory extranodal natural killer (NK)/Tcell lymphoma and leukemia［J］. Cancer Sci, 2008, 99(5): 1016-1020. ［5］ Yamaguchi M, Kwong YL, Kim WS, et al. Phase Ⅱ study of SMILE chemotherapy for newly diagnosed stage Ⅳ, relapsed, or refractory extranodal natural killer (NK)/Tcell lymphoma, nasal type: the NKcell tumor study group study［J］. J Clin Oncol, 2011, 29(33): 44104416. ［6］ Jaccard A, Gachard N, Marin B, et al. Efficacy of Lasparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/Tcell lymphoma, a phase 2 study［J］. Blood, 2011, 117(6): 1834-1839. ［7］ Dong M, He XH, Liu P, et al. Gemcitabinebased combination regimen in patients with peripheral Tcell lymphoma［J］. Med Oncol, 2013, 30(1): 351. ［8］ Ahn HK, Kim SJ, Hwang DW, et al. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/Tcell lymphoma［J］. Invest New Drugs, 2013, 31(2): 469-472. ［9］ Lee J, Suh C, Kang HJ, et al. Phase Ⅰ study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive Tcell or NK/Tcell lymphoma［J］. Ann Oncol, 2008, 19(12): 2079-2083. ［10］ Kim SJ, Yoon DH, Kang HJ, et al. Bortezomib in combination with CHOP as firstline treatment for patients with stage Ⅲ/Ⅳ peripheral Tcell lymphomas: a multicentre, singlearm, phase 2 trial［J］. Eur J Cancer, 2012, 48(17): 3223-3231. ［11］ Kim SJ, Kim K, Park Y, et al. Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral Tcell lymphoma: analysis of efficacy and toxicity［J］. Invest New Drugs, 2012, 30(1): 368375. ［12］ Piccaluga PP, Agostinelli C, Righi S, et al. Expression of CD52 in peripheral Tcell lymphoma［J］. Haematologica, 2007, 92(4): 566-567. ［13］ Huang H, Lin Z, Lin X, et al. Longterm outcomes of patients with newly diagnosed extranodal natural killer/Tcell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a singleinstitution experience［J］. Leuk Lymphoma, 2011, 52(6): 1041-1048. ［14］ Kim BS, Kim DW, Im SA, et al. Effective secondline chemotherapy for extranodal NK/Tcell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone［J］. Ann Oncol, 2009, 20(1): 121-128. ［15］ Lee J, Au WY, Park MJ, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/Tcell lymphoma: a multinational, matched controlled study［J］. Biol Blood Marrow Transplant, 2008, 14(12): 1356-1364. ［16］ Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killercell neoplasms［J］. Br J Haematol, 2005, 130(4): 561-567.

[1]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[2]	Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113.
[3]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[4]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[5]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[6]	Chen Yi, Han Liang, Cai Li.Multivariate analysis of chemotherapy induced oral mucositis in patients with head and neck tumors[J]. Journal of International Oncology, 2022, 49(9): 521-525.
[7]	Chu Xuelei, Mao Yun, Xue Peng, Li Linlu, Chen Meichi, Yuan Chunsheng, Qin Xiaoyan, Zhu Shijie.Effects of chemotherapy dose intensity on short-term efficacy in patients with advanced colon cancer： a study based on real-world data[J]. Journal of International Oncology, 2022, 49(7): 408-415.
[8]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer[J]. Journal of International Oncology, 2022, 49(5): 276-281.
[9]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu.Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(3): 140-145.
[10]	Lao Zheng, Tu Wenyong, Xu Xuanli, Zhang Lin, Shao Ziyang, Shi Huifeng.Nimotuzumab combined with definitive radiotherapy for inoperable locally advanced oral and maxillofacial squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(11): 665-670.
[11]	Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin.Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis[J]. Journal of International Oncology, 2022, 49(1): 45-50.
[12]	Long Xin, Wu Han, Peng Jin, Zhou Fuxiang.Systemic therapy of advanced biliary tract cancer[J]. Journal of International Oncology, 2021, 48(5): 302-307.
[13]	Song Yang, Wang Bin, Xiao He, Chen Chuan, Wang Ge, Geng Mingying.Predictive value of tumor regression rate after induction chemotherapy for survival of patients with locally advanced nasopharyngeal carcinoma[J]. Journal of International Oncology, 2021, 48(3): 156-163.
[14]	Chi Xiuying, Wang Hongbiao, Li Zhifeng, Lin Yingcheng.Progression in the therapies of relapse or metastatic esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2021, 48(12): 755-759.
[15]	Chen Lina, Guo Zhi, Liu Xuanyong, Chen Xiao, Zhang Yihuizhi, Li Xumian, Wei Liya, Wang Yueqiao, Xie Jing.Application study of EAC mobilization scheme in autologous hematopoietic stem cell transplantation of lymphoma[J]. Journal of International Oncology, 2021, 48(11): 666-672.